Rousseau Raphael 4
4 · Gritstone Oncology, Inc. · Filed Jan 21, 2021
Insider Transaction Report
Form 4
Rousseau Raphael
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2021-01-19$0.76/sh+20,000$15,200→ 20,000 total - Exercise/Conversion
Common Stock
2021-01-20$0.76/sh+10,000$7,600→ 10,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-01-19−20,000→ 135,326 totalExercise: $0.76Exp: 2027-05-17→ Common Stock (20,000 underlying) - Sale
Common Stock
2021-01-19$17.53/sh−20,000$350,564→ 0 total - Sale
Common Stock
2021-01-20$25.07/sh−10,000$250,705→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-01-20−10,000→ 125,326 totalExercise: $0.76Exp: 2027-05-17→ Common Stock (10,000 underlying)
Footnotes (4)
- [F1]The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.
- [F2]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $15.00 to $20.04 per share. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.00 to $25.17 per share. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The stock option vests and becomes exercisable with respect to 25% of the total number of shares on April 17, 2018. The remaining shares vest and become exercisable in equal monthly installments over the following 36 months.